Search results
Showing 1381 to 1395 of 2548 results for methods
RespiraSense for continuously monitoring respiratory rate (MIB299)
NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
advanced care planning and the behaviour of healthcare professionals. A mixed-methods approach (quantitative and qualitative evidence)...
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
UrgoStart for treating diabetic foot ulcers and leg ulcers (HTG502)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs